{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T20:03:15Z","timestamp":1766088195420},"reference-count":42,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The efficacy and tolerability of the combination of hypomethylating agents with venetoclax (HMA-VEN) in patients with newly diagnosed acute myeloid leukemia has been a practice-changing milestone in the field. However, treatment failure and relapse remain major barriers to prolonged survival. TP53 mutation is a predictor of primary induction failure and portends especially poor outcomes. Prelinical data suggest that VEN resistance stems from these genetic changes, which lead to increases in antiapoptotic proteins such as MCL-1 and BCLXL. For patients who discontinue HMA-VEN for reasons other than disease progression, such as post allotransplantation, infection, and personal preference, rechallenge with HMA-VEN at the time of relapse may be considered. For those who progress on HMA-VEN, clinical trials with novel agents or rational drug combinations are preferred if available. If no trial option is available, fit patients may benefit from intensive chemotherapy. Emerging therapies aim to overcome venetoclax resistance, target interactions that promote leukemogenesis, and harness the immune system to irradicate leukemic blasts and stem cells.<\/jats:p>","DOI":"10.1182\/hematology.2023000456","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T15:14:35Z","timestamp":1702048475000},"page":"702-708","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["Novel therapies upon failure of HMA plus venetoclax"],"prefix":"10.1182","volume":"2023","author":[{"given":"Onyee","family":"Chan","sequence":"first","affiliation":[{"name":"Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison R.","family":"Walker","sequence":"additional","affiliation":[{"name":"Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"issue":"7","key":"2023120815084261500_hem2023000456C1","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2023120815084261500_hem2023000456C2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1182\/blood-2022-158518","article-title":"Long-term follow-up of the phase 3 Viale-a clinical trial of venetoclax plus azacitidine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy","volume":"140","author":"Pratz","year":"2022","journal-title":"Blood"},{"issue":"11","key":"2023120815084261500_hem2023000456C3","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"issue":"26","key":"2023120815084261500_hem2023000456C4","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"8","key":"2023120815084261500_hem2023000456C5","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1200\/JCO.21.01546","article-title":"Measurable residual disease response and prognosis in treatment-na\u00efve acute myeloid leukemia with venetoclax and azacitidine","volume":"40","author":"Pratz","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"2023120815084261500_hem2023000456C6","doi-asserted-by":"crossref","first-page":"380","DOI":"10.20517\/cdr.2021.125","article-title":"Venetoclax resistance: mechanistic insights and future strategies","volume":"5","author":"Ong","year":"2022","journal-title":"Cancer Drug Resist"},{"issue":"April","key":"2023120815084261500_hem2023000456C7","article-title":"Advancing the standard: venetoclax combined with intensive induction and consolidation therapy for acute myeloid leukemia","volume":"13","author":"Lachowiez","year":"2022","journal-title":"Ther Adv Hematol"},{"issue":"1","key":"2023120815084261500_hem2023000456C8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/cdd.2017.186","article-title":"BCL-2 family proteins: changing partners in the dance towards death","volume":"25","author":"Kale","year":"2018","journal-title":"Cell Death Differ"},{"issue":"10 June","key":"2023120815084261500_hem2023000456C9","doi-asserted-by":"crossref","first-page":"27696","DOI":"10.1038\/srep27696","article-title":"Targeting MCL-1\/BCL-XL forestalls the acquisition of resistance to ABT-199 in acute myeloid leukemia","volume":"6","author":"Lin","year":"2016","journal-title":"Sci Rep"},{"issue":"8","key":"2023120815084261500_hem2023000456C10","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/s43018-020-0103-x","article-title":"Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia","volume":"1","author":"Zhang","year":"2020","journal-title":"Nat Cancer"},{"issue":"1","key":"2023120815084261500_hem2023000456C11","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41392-022-00958-4","article-title":"Correction: activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"2023120815084261500_hem2023000456C12","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","article-title":"The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells","volume":"9","author":"Nechiporuk","year":"2019","journal-title":"Cancer Discov"},{"issue":"3","key":"2023120815084261500_hem2023000456C13","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3324\/haematol.2018.214882","article-title":"Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia","volume":"105","author":"Kuusanm\u00e4ki","year":"2020","journal-title":"Haematologica"},{"issue":"4","key":"2023120815084261500_hem2023000456C14","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov"},{"issue":"6","key":"2023120815084261500_hem2023000456C15","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/2159-8290.CD-22-0939","article-title":"Combinatorial BCL2 family expression in acute myeloid leukemia stem cells predicts clinical response to azacitidine\/venetoclax","volume":"13","author":"Waclawiczek","year":"2023","journal-title":"Cancer Discov"},{"issue":"14","key":"2023120815084261500_hem2023000456C16","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1080\/10428194.2020.1808213","article-title":"Retreatment with venetoclax and hypomethylating agents among AML patients who have relapsed after initial response and subsequent interruption of therapy","volume":"61","author":"Othman","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"13","key":"2023120815084261500_hem2023000456C17","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1182\/bloodadvances.2022007083","article-title":"Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia","volume":"6","author":"Chua","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"2023120815084261500_hem2023000456C18","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3324\/haematol.2020.252569","article-title":"Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens","volume":"106","author":"Maiti","year":"2021","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2023120815084261500_hem2023000456C19","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1182\/blood-2022-165491","article-title":"Outcome of patients with acute myeloid leukemia following failure of front-line venetoclax plus hypomethylating agent therapy","volume":"140","author":"Ilyas","year":"2022","journal-title":"Blood"},{"issue":"24","key":"2023120815084261500_hem2023000456C20","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/bloodadvances.2021005538","article-title":"Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia","volume":"5","author":"Cherry","year":"2021","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2023120815084261500_hem2023000456C21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2020-136120","article-title":"Venetoclax and azacitidine for newly diagnosed non-elderly adult patients with acute myeloid leukemia and adverse risk features","volume":"136","author":"Gutman","year":"2020","journal-title":"Blood"},{"issue":"8","key":"2023120815084261500_hem2023000456C22","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/ajh.26991","article-title":"Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia","volume":"98","author":"Matthews","year":"2023","journal-title":"Am J Hematol"},{"issue":"13","key":"2023120815084261500_hem2023000456C23","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1182\/bloodadvances.2022007265","article-title":"Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia","volume":"6","author":"Matthews","year":"2022","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2023120815084261500_hem2023000456C24","doi-asserted-by":"crossref","first-page":"6185","DOI":"10.1182\/blood-2022-170168","article-title":"Response to intensive induction chemotherapy after failure of frontline azacitidine+venetoclax in acute myeloid leukemia","volume":"140","author":"McMahon","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2023120815084261500_hem2023000456C25","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/ejh.13527","article-title":"Outcomes of relapsed or refractory acute myeloid leukemia patients failing venetoclax-based salvage therapies","volume":"106","author":"Zucenka","year":"2021","journal-title":"Eur J Haematol"},{"issue":"1","key":"2023120815084261500_hem2023000456C26","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13045-021-01079-1","article-title":"Targeting MCL-1 in cancer: current status and perspectives","volume":"14","author":"Wang","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2023120815084261500_hem2023000456C27","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41408-021-00603-3","article-title":"Effective menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)","volume":"12","author":"Fiskus","year":"2022","journal-title":"Blood Cancer J"},{"issue":"2","key":"2023120815084261500_hem2023000456C28","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1172\/JCI129126","article-title":"Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia","volume":"130","author":"Klossowski","year":"2020","journal-title":"J Clin Invest"},{"issue":"suppl 1","key":"2023120815084261500_hem2023000456C29","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1182\/blood-2022-164849","article-title":"The menin inhibitor SNDX-5613 (revumenib) leads to durable responses in patients (Pts) with KMT2A-rearranged or NPM1 mutant AML: updated results of a phase (Ph) 1 study","volume":"140","author":"Issa","year":"2022","journal-title":"Blood"},{"key":"2023120815084261500_hem2023000456C30","article-title":"Activity, tolerability, and resistance profile of the menin inhibitor ziftomenib in adults with relapsed\/refractory NPM1-mutated AML","author":"Fathi","year":"2023"},{"issue":"11","key":"2023120815084261500_hem2023000456C31","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1038\/s41375-020-0949-z","article-title":"MDM2 inhibition: an important step forward in cancer therapy","volume":"34","author":"Konopleva","year":"2020","journal-title":"Leukemia"},{"issue":"5","key":"2023120815084261500_hem2023000456C32","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1158\/1078-0432.CCR-21-1295","article-title":"Results from a first-in-human phase I study of siremadlin (HDM201) in patients with advanced wild-type TP53 solid tumors and acute leukemia","volume":"28","author":"Stein","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2023120815084261500_hem2023000456C33","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"18","key":"2023120815084261500_hem2023000456C34","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2023120815084261500_hem2023000456C35","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1182\/blood-2021-150014","article-title":"First in human (FIH) FLT3 and SYK inhibitor HM43239 shows single agent activity in patients (pts) with relapsed or refractory (R\/R) FLT3 mutated and wild-type acute myeloid leukemia (AML)","volume":"138","author":"Daver","year":"2021","journal-title":"Blood"},{"issue":"suppl 13","key":"2023120815084261500_hem2023000456C36","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1158\/1538-7445.AM2021-1257","article-title":"Abstract 1257: HM43239, a novel FLT3 inhibitor, has the potential to inhibit mutations resistant to FLT3 inhibitors","volume":"81","author":"Bae","year":"2021","journal-title":"Cancer Research"},{"issue":"8","key":"2023120815084261500_hem2023000456C37","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/bloodadvances.2018017517","article-title":"A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells","volume":"2","author":"Kovtun","year":"2018","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2023120815084261500_hem2023000456C38","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1182\/blood-2019-124963","article-title":"IMGN632, a CD123-alkylating ADC bearing a DNA-alkylating IGN payload, combines effectively with azacitidine and venetoclax in vivo, prolonging survival in preclinical models of human acute myeloid leukemia (AML)","volume":"134","author":"Kuruvilla","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2023120815084261500_hem2023000456C39","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood-2021-146503","article-title":"Safety and efficacy from a phase 1b\/2 study of IMGN632 in combination with azacitidine and venetoclax for patients with CD123-positive acute myeloid leukemia","volume":"138","author":"Daver","year":"2021","journal-title":"Blood"},{"issue":"11","key":"2023120815084261500_hem2023000456C40","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1158\/2159-8290.CD-22-0332","article-title":"TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: biology, current therapy, and future directions","volume":"12","author":"Daver","year":"2022","journal-title":"Cancer Discov"},{"issue":"April","key":"2023120815084261500_hem2023000456C41","first-page":"1","article-title":"Contemporary approach to acute myeloid leukemia therapy in 2022","volume":"42","author":"Roloff","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"suppl 1","key":"2023120815084261500_hem2023000456C42","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2022-170188","article-title":"Phase I\/II study of azacitidine (AZA) with venetoclax (VEN) and magrolimab (Magro) in patients (pts) with newly diagnosed (ND) older\/unfit or high-risk acute myeloid leukemia (AML) and relapsed\/refractory (R\/R) AML","volume":"140","author":"Daver","year":"2022","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2023\/1\/702\/2175737\/702chan.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2023\/1\/702\/2175737\/702chan.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T15:14:54Z","timestamp":1702048494000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2023\/1\/702\/506431\/Novel-therapies-upon-failure-of-HMA-plus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12,8]]},"published-print":{"date-parts":[[2023,12,8]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2023000456","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12,8]]},"published":{"date-parts":[[2023,12,8]]}}}